December 05, 2017 –
On December 5, 2017, FDA approved Novo Nordisk’s semaglutide, a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of type 2 diabetes. Todd Hobbs, MD, Novo Nordisk’s vice president and chief medical officer, spoke with The American Journal of Managed Care® just ahead of FDA’s action.
December 03, 2017 –
Practices now should have at least 1 person who understands analytics, as their prevalence and importance grows in the field, explained Nat Turner, co-founder and CEO of Flatiron Health.
December 02, 2017 –
Bobby Green, MD, MSCE, senior vice president of clinical oncology at Flatiron Health discusses the future of clinical trials and how the software tool, OncoTrials, can be used to help match patients to trials.
December 01, 2017 –
Results from the FOURIER trial have provided convincing data that there is no downside to aggressively lowering cholesterol with PCSK9 inhibitors, and studies have shown there are cardiovascular benefits associated with Repatha, but reimbursement remains challenging, said Eliot A. Brinton, MD, FAHA, FNLA, president of the Utah Lipid Center.
November 30, 2017 –
Linda Schwimmer, president and CEO of the New Jersey Health Care Quality Institute, discusses the impact of the group’s report, Medicaid 2.0, which outlined how the state can bring healthcare transformation principles to a program that consumes a fifth of the state budget. New Jersey elected a new governor in November, and the blueprint was widely seen a policy recommendation for the next administration.
November 25, 2017 –
A non-fasting test to measure low-density lipoprotein (LDL) cholesterol has many advantages for patients and physicians, but payers can also see some benefits, explained Eliot A. Brinton, MD, FAHA, FNLA, president of the Utah Lipid Center.
November 23, 2017 –
Diabetes prevention is about a change in lifestyle that will lead to internalized benefits that reduce risk, explained Paul Chew, MD, chief medical officer of Omada Health.
November 22, 2017 –
Real-world evidence isn't usually used for regulatory decisions, but the FDA is poised to start using it more, and there are challenges to using real-world data in clinical trials that will need to be navigated, said Nat Turner, co-founder and CEO of Flatiron Health.
November 14, 2017 –
As oncology moves toward more deep diagnostic testing and as standard of care continues to quickly evolve, technology advancements are necessary to continue to improve patient access to clinical trials, explained Amy Abernethy, MD, PhD, the chief medical officer, chief scientific officer, and senior vice president of oncology at Flatiron Health.
November 13, 2017 –
New approaches for measuring quality need to be developed to get frontline caregivers involved in the early stages of quality measure decisions, said Peter Aran, MD, medical director of population health management at Blue Cross Blue Shield of Oklahoma.